Replies to post #116703 on Biotech Values

[jq1234]

Novartis’s $48,000 Pill Spurs U.S. Price Increases for Older MS Treatments

http://www.bloomberg.com/news/2011-03-21/novartis-s-48-000-pill-spurs-u-s-price-increases-for-ms-drugs.html

Gilenya is set to lead the market in 2017, Leerink estimates, with $2.9 billion in global sales, and Copaxone would be in second place at $2.7 billion. Total sales of MS drugs will grow to about $15 billion from $10 billion now, Leerink said.

Does $2.7 b estimate for Copaxone take into account of generic from NVS/MNTA?